These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 28582607)
1. Phase II study of intrabone single unit cord blood transplantation for hematological malignancies. Murata M; Maeda Y; Masuko M; Onishi Y; Endo T; Terakura S; Ishikawa Y; Iriyama C; Ushijima Y; Goto T; Fujii N; Tanimoto M; Kobayashi H; Shibasaki Y; Fukuhara N; Inamoto Y; Suzuki R; Kodera Y; Matsushita T; Kiyoi H; Naoe T; Nishida T Cancer Sci; 2017 Aug; 108(8):1634-1639. PubMed ID: 28582607 [TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin. Nishida T; Kobayashi T; Sawa M; Masuda S; Shibasaki Y; Goto T; Fukuhara N; Fujii N; Ikegame K; Sugita J; Ikeda T; Kuwatsuka Y; Suzuki R; Najima Y; Doki N; Kato T; Inagaki Y; Utsu Y; Aotsuka N; Masuko M; Terakura S; Onishi Y; Maeda Y; Okada M; Teshima T; Murata M Ann Hematol; 2021 Mar; 100(3):743-752. PubMed ID: 33427909 [TBL] [Abstract][Full Text] [Related]
3. A prospective multicenter phase II study of intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning. Okada M; Tasaka T; Ikegame K; Aotsuka N; Kobayashi T; Najima Y; Matsuhashi Y; Wada H; Tokunaga H; Masuda S; Utsu Y; Yoshihara S; Kaida K; Daimon T; Ogawa H Eur J Haematol; 2018 Apr; 100(4):335-343. PubMed ID: 29168236 [TBL] [Abstract][Full Text] [Related]
4. [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies]. Sun ZM; Liu HL; Wu Y; Geng LQ; Zheng CC; Tang BL; Zhu XY; Tong J; Wang XB; Ding KY; Wan X; Zhang L; Yao W; Zhang XH; Han YS; Yang HZ; Liu X; Zhu WW; Wu JS; Wang ZY Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2214-9. PubMed ID: 27480651 [TBL] [Abstract][Full Text] [Related]
5. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264 [TBL] [Abstract][Full Text] [Related]
6. Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning. Kanda J; Rizzieri DA; Gasparetto C; Long GD; Chute JP; Sullivan KM; Morris A; Smith CA; Hogge DE; Nitta J; Song K; Niedzwiecki D; Chao NJ; Horwitz ME Biol Blood Marrow Transplant; 2011 Jun; 17(6):867-74. PubMed ID: 20868761 [TBL] [Abstract][Full Text] [Related]
7. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies. Mori T; Aisa Y; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Yamane A; Ikeda Y; Okamoto S Transplant Proc; 2007 Jun; 39(5):1615-9. PubMed ID: 17580201 [TBL] [Abstract][Full Text] [Related]
8. Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. Rocha V; Labopin M; Ruggeri A; Podestà M; Gallamini A; Bonifazi F; Sanchez-Guijo FM; Rovira M; Socie G; Baltadakis I; Michallet M; Deconinck E; Bacigalupo A; Mohty M; Gluckman E; Frassoni F Transplantation; 2013 May; 95(10):1284-91. PubMed ID: 23507699 [TBL] [Abstract][Full Text] [Related]
9. Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies. Okada M; Fujimori Y; Misawa M; Kai S; Nakajima T; Okikawa Y; Satake A; Itoi H; Takatsuka H; Itsukuma T; Nishioka K; Tamaki H; Ikegame K; Hara H; Ogawa H Biol Blood Marrow Transplant; 2008 Aug; 14(8):896-903. PubMed ID: 18640573 [TBL] [Abstract][Full Text] [Related]
10. Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. Horwitz ME; Wease S; Blackwell B; Valcarcel D; Frassoni F; Boelens JJ; Nierkens S; Jagasia M; Wagner JE; Kuball J; Koh LP; Majhail NS; Stiff PJ; Hanna R; Hwang WYK; Kurtzberg J; Cilloni D; Freedman LS; Montesinos P; Sanz G J Clin Oncol; 2019 Feb; 37(5):367-374. PubMed ID: 30523748 [TBL] [Abstract][Full Text] [Related]
11. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630 [TBL] [Abstract][Full Text] [Related]
12. The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. Choe HK; Gergis U; Mayer SA; Nagar H; Phillips AA; Shore TB; Smith MJ; van Besien K Transplantation; 2017 Jan; 101(1):e34-e38. PubMed ID: 27764032 [TBL] [Abstract][Full Text] [Related]
13. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Frassoni F; Gualandi F; Podestà M; Raiola AM; Ibatici A; Piaggio G; Sessarego M; Sessarego N; Gobbi M; Sacchi N; Labopin M; Bacigalupo A Lancet Oncol; 2008 Sep; 9(9):831-9. PubMed ID: 18693069 [TBL] [Abstract][Full Text] [Related]
14. Intrabone Transplantation of a Single Unwashed Umbilical Cord Blood Unit with Antithymocyte Globulin-Free and Sirolimus-Based Graft-versus-Host Disease Prophylaxis: Fast Immune Reconstitution and Long-Term Disease Control in Patients with High-Risk Diseases. Giglio F; Xue E; Barone A; Lorentino F; Greco R; Ruggeri A; Zambelli M; Parisi C; Milani R; Clerici D; Piemontese S; Marktel S; Lazzari L; Marcatti M; Bernardi M; Corti C; Lupo-Stanghellini MT; Ciceri F; Peccatori J Transplant Cell Ther; 2023 Aug; 29(8):519.e1-519.e9. PubMed ID: 37244644 [TBL] [Abstract][Full Text] [Related]
15. Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis. Yamada MF; Miyamura K; Fujiwara T; Kohata K; Okitsu Y; Ohguchi H; Yamamoto J; Yokoyama H; Tomiya Y; Ishizawa K; Kameoka J; Harigae H Transplant Proc; 2008 Dec; 40(10):3637-42. PubMed ID: 19100456 [TBL] [Abstract][Full Text] [Related]
16. Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow. Misawa M; Kai S; Okada M; Nakajima T; Nomura K; Wakae T; Toda A; Itoi H; Takatsuka H; Itsukuma T; Nishioka K; Fujimori Y; Ogawa H; Hara H Int J Hematol; 2006 Jan; 83(1):74-9. PubMed ID: 16443557 [TBL] [Abstract][Full Text] [Related]
17. [Unrelated umbilical cord blood transplantation with TBI/Ara-c/CY non-ATG conditioning regimen for adults with hematologic malignancies]. Sun ZM; Liu HL; Geng LQ; Zhou CY; Wang XB; Ding KY; Tong J; Zhu WB; Liu X; Wang ZY Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(24):1660-4. PubMed ID: 22944153 [TBL] [Abstract][Full Text] [Related]
18. Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study. Sun Z; Liu H; Luo C; Geng L; Zheng C; Tang B; Zhu X; Tong J; Wang X; Ding K; Wan X; Zhang L; Yao W; Song K; Zhang X; Wu Y; Yang H; Han Y; Liu X; Zhu W; Wu J; Wang Z Int J Cancer; 2018 Aug; 143(3):699-708. PubMed ID: 29473150 [TBL] [Abstract][Full Text] [Related]
19. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989 [TBL] [Abstract][Full Text] [Related]
20. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]